|
|
|
题名
|
作者
|
年代
|
出处
|
被引量
|
| 1 | Stem Cell Ophthalmology Treatment Study(SCOTS) for retinal and optic nerve diseases: a case report of improvement in relapsing auto-immune optic neuropathy显示文摘We present the results from a patient with relapsing optic neuropathy treated within the Stem Cell Ophthalmology Treatment Study(SCOTS). SCOTS is an Institutional Review Board approved clinical trial and has become the largest ophthalmology stem cell study registered at the National Institutes of Health to date(www.clinicaltrials.gov Identifier NCT 01920867). SCOTS utilizes autologous bone marrow-derived stem cells(BMSCs) for treatment of retinal and optic nerve diseases. Pre-treatment and post-treatment comprehensive eye exams of a 54 year old female patient were performed both at the Florida Study Center, USA and at The Eye Center of Columbus, USA. As a consequence of a relapsing optic neuritis, the patient's previously normal visual acuity decreased to between 20/350 and 20/400 in the right eye and to 20/70 in the left eye. Significant visual field loss developed bilaterally. The patient underwent a right eye vitrectomy with injection of BMSCs into the optic nerve of the right eyeand retrobulbar, subtenon and intravitreal injection of BMSCs in the left eye. At 15 months after SCOTS treatment, the patient's visual acuity had improved to 20/150 in the right eye and 20/20 in the left eye. Bilateral visual fields improved markedly. Both macular thickness and fast retinal nerve fiber layer thickness were maximally improved at 3 and 6 months after SCOTS treatment. The patient also reduced her mycophenylate dose from 1,500 mg per day to 500 mg per day and required no steroid pulse therapy during the 15-month follow up. | Jeffrey N.Weiss Steven Levy Susan C.Benes | 2015 | Neural Regeneration Research2015，10，9： | 6 |
| 2 | Stem Cell Ophthalmology Treatment Study(SCOTS) for retinal and optic nerve diseases: a preliminary report显示文摘In this report, we present the results of a single patient with optic neuropathy treated within the Stem Cell Ophthalmology Treatment Study(SCOTS). SCOTS is an Institutional Review Board approved clinical trial and is the largest ophthalmology stem cell study registered at the National Institutes of Health to date- www.clinicaltrials.gov Identifier NCT 01920867. SCOTS utilizes autologous bone marrow-derived stem cells in the treatment of optic nerve and retinal diseases. Pre- and post-treatment comprehensive eye exams were independently performed at the Wilmer Eye Institute at the Johns Hopkins Hospital, USA. A 27 year old female patient had lost vision approximately 5 years prior to enrollment in SCOTS. Pre-treatment best-corrected visual acuity at the Wilmer Eye Institute was 20/800 Right Eye(OD) and 20/4,000 Left Eye(OS). Four months following treatment in SCOTS, the central visual acuity had improved to 20/100 OD and 20/40 OS. | Jeffrey N.Weiss Steven Levy Alexis Malkin | 2015 | Neural Regeneration Research2015，10，6： | 5 |
| 3 | Moral Hazard in Home Equity Conversion显示文摘 | Robert J.Shiller Allan N.Weiss | 2003 | Real Estate Economics2003，，1： | 1 |
| 4 | Moral Hazard in Home Equity Conversion显示文摘 | Robert J.Shiller Allan N.Weiss | 2003 | Real Estate Economics2003，，1： | 1 |
| 5 | Making QT Correction Simple is Complicated显示文摘 | NOEL G.BOYLE JAMES N.WEISS | 2003 | Journal of Cardiovascular Electrophysiology2003，，： | 1 |
您所在的机构暂未开通此部分的功能，请联系管理员